Company intelligence / Profile preview
Ruga Corporation
Frisco, Texas, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Ruga-S6, an engineered decoy soluble AXL receptor (Fc-fusion protein), demonstrated strong anti-tumor efficacy and tolerability in preclinical models of AML (including FLT3-ITD+ patient-derived cells) and solid tumors like ovarian cancer (>95% disease-free in resistant models), with plans for IND filing by Q1 2017.[1]
- Therapeutic areas
- Oncology
- Modalities
- Fc-fusion protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ruga Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ruga Corporation.